Emmaus Life Sciences, Inc. (EMMA)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.57 Million USD | 154.24% |
| 2022 | -5.49 Million USD | 18.09% |
| 2021 | -12.76 Million USD | -47400.0% |
| 2020 | 28 Thousand USD | 100.21% |
| 2019 | -26.98 Million USD | 19.09% |
| 2018 | -10.13 Million USD | -43.55% |
| 2017 | -7.05 Million USD | -75.39% |
| 2016 | -3.19 Million USD | -84.37% |
| 2015 | -3.11 Million USD | 55.82% |
| 2014 | -2.63 Million USD | -530.8% |
| 2013 | -4.18 Million USD | 123.94% |
| 2012 | -4.78 Million USD | 17.71% |
| 2011 | -1.28 Million USD | -12.14% |
| 2010 | -7.8 Million USD | 12.85% |
| 2009 | -6.67 Million USD | -8.87% |
| 2008 | -5.46 Million USD | -62.9% |
| 2007 | -3.24 Million USD | -1655.46% |
| 2006 | 553.8 Thousand USD | -181.58% |
| 2005 | -1.09 Million USD | 73.99% |
| 2004 | -261.08 Thousand USD | -88.21% |
| 2003 | -138.62 Thousand USD | -1237.11% |
| 2002 | -10.37 Thousand USD | -12.72% |
| 2001 | -9204.00 USD | -34.54% |
| 2000 | -6841.00 USD | 77.2% |
| 1999 | -30 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -2.58 Million USD | -279.21% |
| 2024 Q2 | 723 Thousand USD | 51.58% |
| 2023 Q4 | 1.36 Million USD | 910.12% |
| 2023 Q2 | 3.06 Million USD | 363.43% |
| 2023 Q1 | -1.16 Million USD | 30.57% |
| 2023 FY | - USD | 154.24% |
| 2023 Q3 | -168 Thousand USD | -105.47% |
| 2022 Q3 | -904 Thousand USD | 49.41% |
| 2022 Q4 | -1.67 Million USD | -85.62% |
| 2022 FY | - USD | 18.09% |
| 2022 Q1 | -3.39 Million USD | 38.19% |
| 2022 Q2 | -1.78 Million USD | 47.39% |
| 2021 Q3 | -488 Thousand USD | -556.07% |
| 2021 Q2 | 107 Thousand USD | 104.94% |
| 2021 Q1 | -2.16 Million USD | -515.36% |
| 2021 FY | - USD | -47400.0% |
| 2021 Q4 | -5.49 Million USD | -1026.23% |
| 2020 Q2 | -1.52 Million USD | -296.9% |
| 2020 Q1 | 775 Thousand USD | 26.63% |
| 2020 Q3 | 247 Thousand USD | 116.19% |
| 2020 Q4 | 521 Thousand USD | 110.93% |
| 2020 FY | - USD | 100.21% |
| 2019 FY | - USD | 19.09% |
| 2019 Q2 | -2.67 Million USD | -0.68% |
| 2019 Q3 | -7.81 Million USD | -192.45% |
| 2019 Q1 | -2.65 Million USD | -0.1% |
| 2019 Q4 | 612 Thousand USD | 107.83% |
| 2018 Q4 | -2.65 Million USD | -38.62% |
| 2018 Q2 | -2.88 Million USD | -10.95% |
| 2018 Q1 | -2.59 Million USD | 4.89% |
| 2018 Q3 | -1.91 Million USD | 33.66% |
| 2018 FY | - USD | -43.55% |
| 2017 Q3 | -2.67 Million USD | -73.98% |
| 2017 Q1 | -1.4 Million USD | 1.26% |
| 2017 Q2 | -1.53 Million USD | -9.17% |
| 2017 Q4 | -2.73 Million USD | -2.03% |
| 2017 FY | - USD | -75.39% |
| 2016 Q1 | -1.47 Million USD | -186.57% |
| 2016 Q4 | -1.42 Million USD | 58.95% |
| 2016 Q3 | -3.47 Million USD | -351.38% |
| 2016 FY | - USD | -84.37% |
| 2016 Q2 | -770.7 Thousand USD | 47.77% |
| 2015 Q3 | 111.3 Thousand USD | 117.4% |
| 2015 Q1 | -916.2 Thousand USD | -24.3% |
| 2015 FY | - USD | 55.82% |
| 2015 Q4 | 1.7 Million USD | 1431.54% |
| 2015 Q2 | -639.6 Thousand USD | 30.19% |
| 2014 FY | - USD | -530.8% |
| 2014 Q3 | -921.1 Thousand USD | 9.0% |
| 2014 Q4 | -737.1 Thousand USD | 19.98% |
| 2014 Q1 | -938.1 Thousand USD | 54.6% |
| 2014 Q2 | -1.01 Million USD | -7.9% |
| 2013 Q1 | -1.21 Million USD | -13.91% |
| 2013 FY | - USD | 123.94% |
| 2013 Q3 | 4.59 Million USD | 490.83% |
| 2013 Q4 | -2.06 Million USD | -144.94% |
| 2013 Q2 | -1.17 Million USD | 2.9% |
| 2012 Q4 | -1.06 Million USD | -47.11% |
| 2012 Q2 | -6.88 Million USD | -387.51% |
| 2012 FY | - USD | 17.71% |
| 2012 Q1 | -1.41 Million USD | 11.94% |
| 2012 Q3 | -723 Thousand USD | 89.5% |
| 2011 Q2 | -5.88 Million USD | -325.84% |
| 2011 FY | - USD | -12.14% |
| 2011 Q4 | -1.6 Million USD | -152.11% |
| 2011 Q1 | 2.6 Million USD | 146.41% |
| 2011 Q3 | 3.07 Million USD | 152.31% |
| 2010 Q2 | -1.41 Million USD | -2.21% |
| 2010 Q1 | -1.38 Million USD | 25.09% |
| 2010 FY | - USD | 12.85% |
| 2010 Q3 | -489.1 Thousand USD | 65.55% |
| 2010 Q4 | -5.61 Million USD | -1048.27% |
| 2009 Q3 | -1.78 Million USD | -51.11% |
| 2009 Q4 | -1.85 Million USD | -3.98% |
| 2009 FY | - USD | -8.87% |
| 2009 Q1 | -1.45 Million USD | -1.69% |
| 2009 Q2 | -1.18 Million USD | 18.81% |
| 2008 Q2 | -1.57 Million USD | -20.7% |
| 2008 Q1 | -1.3 Million USD | -26.16% |
| 2008 Q4 | -1.42 Million USD | 2.47% |
| 2008 FY | - USD | -62.9% |
| 2008 Q3 | -1.46 Million USD | 7.02% |
| 2007 FY | - USD | -1655.46% |
| 2007 Q4 | -1.03 Million USD | 33.63% |
| 2007 Q3 | -1.56 Million USD | -164.18% |
| 2007 Q1 | -1.37 Million USD | -2278.46% |
| 2007 Q2 | -590.5 Thousand USD | 57.18% |
| 2006 Q4 | -57.98 Thousand USD | 70.48% |
| 2006 Q3 | -196.42 Thousand USD | 13.07% |
| 2006 Q2 | -225.96 Thousand USD | -4893.68% |
| 2006 Q1 | -4525.00 USD | 68.98% |
| 2006 FY | - USD | -181.58% |
| 2005 Q2 | 942.00 USD | 110.02% |
| 2005 FY | - USD | 73.99% |
| 2005 Q4 | -14.58 Thousand USD | -163.72% |
| 2005 Q3 | -5532.00 USD | -687.26% |
| 2005 Q1 | -9400.00 USD | 91.08% |
| 2004 Q4 | -105.33 Thousand USD | 26.6% |
| 2004 FY | - USD | -88.21% |
| 2004 Q1 | -2173.00 USD | 44.72% |
| 2004 Q3 | -143.51 Thousand USD | -457.67% |
| 2004 Q2 | -25.73 Thousand USD | -1084.26% |
| 2003 FY | - USD | -1237.11% |
| 2003 Q1 | -1776.00 USD | 55.11% |
| 2003 Q4 | -3931.00 USD | 93.19% |
| 2003 Q3 | -57.75 Thousand USD | 23.17% |
| 2003 Q2 | -75.17 Thousand USD | -4132.6% |
| 2002 Q1 | -2570.00 USD | 20.19% |
| 2002 FY | - USD | -12.72% |
| 2002 Q4 | -3956.00 USD | -170.4% |
| 2002 Q3 | -1591.00 USD | 35.21% |
| 2002 Q2 | -2258.00 USD | 12.14% |
| 2001 Q2 | -603.00 USD | 86.58% |
| 2001 FY | - USD | -34.54% |
| 2001 Q1 | -4655.00 USD | 52.91% |
| 2001 Q4 | -3220.00 USD | -325.93% |
| 2001 Q3 | -744.00 USD | -19.62% |
| 2000 Q4 | -10 Thousand USD | 0.0% |
| 2000 Q2 | -10 Thousand USD | 0.0% |
| 2000 FY | - USD | 77.2% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 100.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q3 | - USD | 100.0% |
| 1999 Q2 | -10 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 105.028% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 160.247% |
| SQZ Biotechnologies Company | -64.14 Million USD | 105.569% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 120.564% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 96.202% |
| Mesoblast Limited | -62.38 Million USD | 105.725% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 332.545% |
| Genus plc | 73.7 Million USD | 95.153% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 154.027% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 200.705% |
| Marizyme, Inc. | -34.28 Million USD | 110.42% |
| ContraFect Corporation | -64.99 Million USD | 105.495% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 140.72% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 178.918% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 354.814% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 235.075% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 253.712% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 789.514% |
| Accustem Sciences Inc. | -3.74 Million USD | 195.344% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 107.407% |
| EV Biologics, Inc. | -1.26 Million USD | 381.896% |
| Q BioMed Inc. | -617.62 Thousand USD | 678.342% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 664.827% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 256.359% |
| Biomind Labs Inc. | -1.03 Million USD | 445.271% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 63.835% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 149.879% |
| Skye Bioscience, Inc. | -13.54 Million USD | 126.366% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 340.149% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 14388.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 191.959% |
| IMV Inc. | -35.52 Million USD | 110.055% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 122.508% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 242.768% |
| GB Sciences, Inc. | -1.41 Million USD | 351.57% |
| Alpha Cognition Inc. | -9.7 Million USD | 136.803% |
| HST Global, Inc. | -5303.00 USD | 67458.099% |
| CSL Limited | 4.78 Billion USD | 99.925% |
| Halberd Corporation | -74.27 Thousand USD | 4908.896% |
| Enzolytics Inc. | -2.12 Million USD | 268.329% |
| Resverlogix Corp. | -11.74 Million USD | 130.421% |
| Affymax, Inc. | -14.29 Million USD | 124.988% |
| SYBLEU INC | -141.57 Thousand USD | 2623.116% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 216.617% |
| argenx SE | -216.02 Million USD | 101.654% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 106.455% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -193.509% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 338.307% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -842.868% |
| AVAX Technologies, Inc. | -6.11 Million USD | 158.436% |
| Zenith Capital Corp. | -8.6 Million USD | 141.506% |
| Genscript Biotech Corporation | -248.71 Million USD | 101.436% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 20603.989% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 246.007% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 2129.265% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 109.012% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 223.499% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 441.39% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -53023.141% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 304.114% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 285.953% |
| BioStem Technologies, Inc. | -7.55 Million USD | 147.288% |
| ONE Bio Corp. | 13.61 Million USD | 73.76% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 2072.522% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 273.651% |
| Agentix Corp. | -1.37 Million USD | 360.396% |
| LadRx Corporation | 412.28 Thousand USD | -766.395% |
| Cell Source, Inc. | -4.27 Million USD | 183.604% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 1072.711% |
| Regen BioPharma, Inc. | 1.46 Million USD | -143.664% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 481.237% |
| NovAccess Global Inc. | -1.03 Million USD | 445.188% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 59.656% |
| Itoco Inc. | -1.86 Million USD | 291.119% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 1040.941% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 420.072% |
| Kadimastem Ltd | -2.62 Million USD | 236.108% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 1593.623% |
| CytoDyn Inc. | -18.02 Million USD | 119.813% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 4619.86% |
| Mobile Lads Corp. | -2.24 Million USD | 259.382% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 29309.257% |
| Qrons Inc. | -40.08 Thousand USD | 9011.953% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 835.467% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -577.242% |
| Rebus Holdings, Inc. | -951 Thousand USD | 475.605% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 436.343% |
| International Stem Cell Corporation | 202 Thousand USD | -1668.317% |
| Bioxytran, Inc. | -3.82 Million USD | 193.504% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 6885.714% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 245.089% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 109.958% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 8037.778% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 230.46% |
| Neutra Corp. | -181.24 Thousand USD | 2070.791% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 117.719% |
| PureTech Health plc | -11.62 Million USD | 130.722% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 117.72% |
| IXICO plc | -707 Thousand USD | 605.233% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 146.48% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 107.388% |
| CSL Limited | 4.73 Billion USD | 99.925% |
| Cellectis S.A. | -92.63 Million USD | 103.856% |